DEKA Biosciences Overview
- Founded
- 2019
- Status
- Private
- Employees
- 12
- Latest Deal Type
- Series A1
- Latest Deal Amount
- $20M
- Investors
- 5
DEKA Biosciences General Information
Description
Operator of a biotechnology company intended to develop and deliver life-changing medicines for cancer and inflammatory diseases. The company has developed disease-specific products that maximize patient benefits through improved pharmacokinetics/pharmacodynamics (PK/PD) function via targeted delivery of dual and complementary cytokines to affected tissues or cells, providing patients with curative treatment options for cancer, autoimmune and infectious diseases.
Contact Information
Website
www.dekabiosciences.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 20271 Goldenrod Lane
- Suite 2087 Germantown
- MD 20876
- United States
DEKA Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC (Series A1) | 16-Nov-2021 | $20M | 0000 | 0000 | Completed | Generating Revenue |
DEKA Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-1 | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A-2 | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
DEKA Biosciences Patents
DEKA Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210214782-A1 | Method of using genetic markers, single nucleotide polymorphisms and/or indels to determine responsiveness to il-10 or il-10 derivative treatment | Pending | 09-Jan-2020 | 00000000000 | |
| CA-3132385-A1 | Il-10 variant molecules and methods of treating inflammatory disease and oncology | Pending | 06-Mar-2019 | 000000000 | |
| US-10981966-B2 | Il-10 variant molecules conjugated with antibody variable domain regions | Active | 06-Mar-2019 | 000000000 | 0 |
| US-10858412-B2 | Antibody variable domain regions fused to il-10 variant molecules | Active | 06-Mar-2019 | 000000000 | |
| US-10975134-B2 | Antibody-il-10 fusion proteins | Active | 06-Mar-2019 | A61P29/00 | 0 |
DEKA Biosciences Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| John Mumm Ph.D | Co-Founder & Chief Executive Officer | ||
| John Conner | Chief Operations Officer | ||
| Pavel Khrimian | Co-Founder & Chief Business Officer |
DEKA Biosciences Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialDEKA Biosciences Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Alexandria Venture Investments | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| Echo Investment Capital | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| Leaps by Bayer | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| Lumira Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Viva BioInnovator | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |